Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Significance of gene mutations in the Wnt signaling pathway in traditional serrated adenomas of the colon and rectum.

Nakanishi H, Sawada T, Kaizaki Y, Ota R, Suzuki H, Yamamoto E, Aoki H, Eizuka M, Hasatani K, Takahashi N, Inagaki S, Ebi M, Kato H, Kubota E, Kataoka H, Takahashi S, Tokino T, Minamoto T, Sugai T, Sasaki Y.

PLoS One. 2020 Feb 24;15(2):e0229262. doi: 10.1371/journal.pone.0229262. eCollection 2020.

2.

Renal angiomyolipoma (AML) harboring a missense mutation of TSC2 with copy-neutral loss of heterozygosity (CN-LOH).

Idogawa M, Hida T, Tanaka T, Ohira N, Tange S, Sasaki Y, Uhara H, Masumori N, Tokino T, Natori H.

Cancer Biol Ther. 2020 Apr 2;21(4):315-319. doi: 10.1080/15384047.2019.1702406. Epub 2019 Dec 17.

PMID:
31847710
3.

Chemotherapy after progression on nivolumab is essential for responders with genetic alterations of driver gene: Review of two recurrent/metastatic oral squamous cell carcinoma patients.

Ogi K, Kobayashi J, Nakagaki T, Okamoto J, Koike K, Hirokawa N, Someya M, Sakamoto H, Takada K, Tokino T, Sasaki Y, Hiratsuka H, Miyazaki A.

Oral Oncol. 2020 Mar;102:104509. doi: 10.1016/j.oraloncology.2019.104509. Epub 2019 Dec 12. No abstract available.

PMID:
31839407
4.

p53-induced ARVCF modulates the splicing landscape and supports the tumor suppressive function of p53.

Suzuki N, Idogawa M, Tange S, Ohashi T, Sasaki Y, Nakase H, Tokino T.

Oncogene. 2020 Mar;39(10):2202-2211. doi: 10.1038/s41388-019-1133-7. Epub 2019 Dec 11.

PMID:
31827232
5.

Pathogenesis of multiple pancreatic cancers involves multicentric carcinogenesis and intrapancreatic metastasis.

Fujita Y, Matsuda S, Sasaki Y, Masugi Y, Kitago M, Yagi H, Abe Y, Shinoda M, Tokino T, Sakamoto M, Kitagawa Y.

Cancer Sci. 2020 Feb;111(2):739-748. doi: 10.1111/cas.14268. Epub 2020 Jan 15.

6.

Genomic characterization for familial cases with urothelial carcinoma.

Shindo T, Hirobe M, Adachi Y, Sasaki Y, Tokino T, Masumori N.

Int Cancer Conf J. 2019 Jun 27;8(4):185-189. doi: 10.1007/s13691-019-00381-7. eCollection 2019 Oct.

PMID:
31559120
7.

FGFR Signaling as a Candidate Therapeutic Target for Cancers Resistant to Carbon Ion Radiotherapy.

Darwis NDM, Nachankar A, Sasaki Y, Matsui T, Noda SE, Murata K, Tamaki T, Ando K, Okonogi N, Shiba S, Irie D, Kaminuma T, Kumazawa T, Anakura M, Yamashita S, Hirakawa T, Kakoti S, Hirota Y, Tokino T, Iwase A, Ohno T, Shibata A, Oike T, Nakano T.

Int J Mol Sci. 2019 Sep 14;20(18). pii: E4563. doi: 10.3390/ijms20184563.

8.

Corrigendum to "Prognostic Effect of Long Noncoding RNA NEAT1 Expression Depends on p53 Mutation Status in Cancer".

Idogawa M, Nakase H, Sasaki Y, Tokino T.

J Oncol. 2019 Aug 7;2019:4757046. doi: 10.1155/2019/4757046. eCollection 2019.

9.

Prognostic Effect of Long Noncoding RNA NEAT1 Expression Depends on p53 Mutation Status in Cancer.

Idogawa M, Nakase H, Sasaki Y, Tokino T.

J Oncol. 2019 May 2;2019:4368068. doi: 10.1155/2019/4368068. eCollection 2019. Erratum in: J Oncol. 2019 Aug 7;2019:4757046.

10.

UHRF1 depletion and HDAC inhibition reactivate epigenetically silenced genes in colorectal cancer cells.

Niinuma T, Kitajima H, Kai M, Yamamoto E, Yorozu A, Ishiguro K, Sasaki H, Sudo G, Toyota M, Hatahira T, Maruyama R, Tokino T, Nakase H, Sugai T, Suzuki H.

Clin Epigenetics. 2019 May 7;11(1):70. doi: 10.1186/s13148-019-0668-3.

11.

A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors.

Fukamachi H, Kim SK, Koh J, Lee HS, Sasaki Y, Yamashita K, Nishikawaji T, Shimada S, Akiyama Y, Byeon SJ, Bae DH, Okuno K, Nakagawa M, Tanioka T, Inokuchi M, Kawachi H, Tsuchiya K, Kojima K, Tokino T, Eishi Y, Kim YS, Kim WH, Yuasa Y, Tanaka S.

J Exp Clin Cancer Res. 2019 Mar 12;38(1):127. doi: 10.1186/s13046-019-1121-3.

12.

Targeted next-generation sequencing of 50 cancer-related genes in Japanese patients with oral squamous cell carcinoma.

Nakagaki T, Tamura M, Kobashi K, Omori A, Koyama R, Idogawa M, Ogi K, Hiratsuka H, Tokino T, Sasaki Y.

Tumour Biol. 2018 Sep;40(9):1010428318800180. doi: 10.1177/1010428318800180.

PMID:
30226113
13.

Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy.

Nuryadi E, Sasaki Y, Hagiwara Y, Permata TBM, Sato H, Komatsu S, Yoshimoto Y, Murata K, Ando K, Kubo N, Okonogi N, Takakusagi Y, Adachi A, Iwanaga M, Tsuchida K, Tamaki T, Noda SE, Hirota Y, Shibata A, Ohno T, Tokino T, Oike T, Nakano T.

Oncotarget. 2018 Aug 24;9(66):32642-32652. doi: 10.18632/oncotarget.25982. eCollection 2018 Aug 24.

14.

DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.

Ishiguro K, Kitajima H, Niinuma T, Ishida T, Maruyama R, Ikeda H, Hayashi T, Sasaki H, Wakasugi H, Nishiyama K, Shindo T, Yamamoto E, Kai M, Sasaki Y, Tokino T, Nakase H, Suzuki H.

Haematologica. 2019 Jan;104(1):155-165. doi: 10.3324/haematol.2018.191262. Epub 2018 Aug 31.

15.

Screening for long noncoding RNAs associated with oral squamous cell carcinoma reveals the potentially oncogenic actions of DLEU1.

Nishiyama K, Maruyama R, Niinuma T, Kai M, Kitajima H, Toyota M, Hatanaka Y, Igarashi T, Kobayashi JI, Ogi K, Dehari H, Miyazaki A, Yorozu A, Yamamoto E, Idogawa M, Sasaki Y, Sugai T, Tokino T, Hiratsuka H, Suzuki H.

Cell Death Dis. 2018 Aug 1;9(8):826. doi: 10.1038/s41419-018-0893-2.

16.

Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment.

Wakasugi H, Takahashi H, Niinuma T, Kitajima H, Oikawa R, Matsumoto N, Takeba Y, Otsubo T, Takagi M, Ariizumi Y, Suzuki M, Okuse C, Iwabuchi S, Nakano M, Akutsu N, Kang JH, Matsui T, Yamada N, Sasaki H, Yamamoto E, Kai M, Sasaki Y, Sasaki S, Tanaka Y, Yotsuyanagi H, Tsutsumi T, Yamamoto H, Tokino T, Nakase H, Suzuki H, Itoh F.

Cancer Lett. 2018 Oct 10;434:91-100. doi: 10.1016/j.canlet.2018.07.019. Epub 2018 Jul 17.

PMID:
30026054
17.

Surface microstructures are associated with mutational intratumoral heterogeneity in colorectal tumors.

Harada T, Yamamoto E, Yamano HO, Aoki H, Matsushita HO, Yoshikawa K, Takagi R, Harada E, Tanaka Y, Yoshida Y, Eizuka M, Yorozu A, Sudo G, Kitajima H, Niinuma T, Kai M, Sasaki Y, Tokino T, Sugai T, Nakase H, Suzuki H.

J Gastroenterol. 2018 Dec;53(12):1241-1252. doi: 10.1007/s00535-018-1481-z. Epub 2018 Jun 11.

PMID:
29948303
18.

Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.

Takashima Y, Sasaki Y, Hayano A, Homma J, Fukai J, Iwadate Y, Kajiwara K, Ishizawa S, Hondoh H, Tokino T, Yamanaka R.

Oncotarget. 2018 Jun 8;9(44):27471-27486. doi: 10.18632/oncotarget.25463. eCollection 2018 Jun 8.

19.

Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer.

Shindo T, Niinuma T, Nishiyama N, Shinkai N, Kitajima H, Kai M, Maruyama R, Tokino T, Masumori N, Suzuki H.

Oncotarget. 2018 May 11;9(36):24457-24469. doi: 10.18632/oncotarget.25326. eCollection 2018 May 11.

20.

Targeted sequencing reveals genetic variants associated with sensitivity of 79 human cancer xenografts to anticancer drugs.

Udagawa C, Sasaki Y, Suemizu H, Ohnishi Y, Ohnishi H, Tokino T, Zembutsu H.

Exp Ther Med. 2018 Feb;15(2):1339-1359. doi: 10.3892/etm.2017.5533. Epub 2017 Nov 21.

21.

Downregulation of miR-186 is associated with metastatic recurrence of gastrointestinal stromal tumors.

Niinuma T, Kai M, Kitajima H, Yamamoto E, Harada T, Maruyama R, Nobuoka T, Nishida T, Kanda T, Hasegawa T, Tokino T, Sugai T, Shinomura Y, Nakase H, Suzuki H.

Oncol Lett. 2017 Nov;14(5):5703-5710. doi: 10.3892/ol.2017.6911. Epub 2017 Sep 8.

22.

Identification and characterization of a metastatic suppressor BRMS1L as a target gene of p53.

Koyama R, Tamura M, Nakagaki T, Ohashi T, Idogawa M, Suzuki H, Tokino T, Sasaki Y.

Cancer Sci. 2017 Dec;108(12):2413-2421. doi: 10.1111/cas.13420. Epub 2017 Nov 6.

23.

Profiling cancer-related gene mutations in oral squamous cell carcinoma from Japanese patients by targeted amplicon sequencing.

Nakagaki T, Tamura M, Kobashi K, Koyama R, Fukushima H, Ohashi T, Idogawa M, Ogi K, Hiratsuka H, Tokino T, Sasaki Y.

Oncotarget. 2017 Jul 15;8(35):59113-59122. doi: 10.18632/oncotarget.19262. eCollection 2017 Aug 29.

24.

Fledglings in p53 signaling network.

Tokino T, Idogawa M, Sasaki Y.

Oncotarget. 2017 Jul 14;8(34):55768-55769. doi: 10.18632/oncotarget.19229. eCollection 2017 Aug 22. No abstract available.

25.

Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation.

Einaga N, Yoshida A, Noda H, Suemitsu M, Nakayama Y, Sakurada A, Kawaji Y, Yamaguchi H, Sasaki Y, Tokino T, Esumi M.

PLoS One. 2017 May 12;12(5):e0176280. doi: 10.1371/journal.pone.0176280. eCollection 2017.

26.

Long non-coding RNA NEAT1 is a transcriptional target of p53 and modulates p53-induced transactivation and tumor-suppressor function.

Idogawa M, Ohashi T, Sasaki Y, Nakase H, Tokino T.

Int J Cancer. 2017 Jun 15;140(12):2785-2791. doi: 10.1002/ijc.30689. Epub 2017 Mar 27.

27.

p53 mediates the suppression of cancer cell invasion by inducing LIMA1/EPLIN.

Ohashi T, Idogawa M, Sasaki Y, Tokino T.

Cancer Lett. 2017 Apr 1;390:58-66. doi: 10.1016/j.canlet.2016.12.034. Epub 2017 Jan 13.

PMID:
28093207
28.

TET1 Depletion Induces Aberrant CpG Methylation in Colorectal Cancer Cells.

Kai M, Niinuma T, Kitajima H, Yamamoto E, Harada T, Aoki H, Maruyama R, Toyota M, Sasaki Y, Sugai T, Tokino T, Nakase H, Suzuki H.

PLoS One. 2016 Dec 15;11(12):e0168281. doi: 10.1371/journal.pone.0168281. eCollection 2016.

29.

Identification and characterization of the intercellular adhesion molecule-2 gene as a novel p53 target.

Sasaki Y, Tamura M, Takeda K, Ogi K, Nakagaki T, Koyama R, Idogawa M, Hiratsuka H, Tokino T.

Oncotarget. 2016 Sep 20;7(38):61426-61437. doi: 10.18632/oncotarget.11366.

30.

Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress.

Saijo H, Hirohashi Y, Torigoe T, Horibe R, Takaya A, Murai A, Kubo T, Kajiwara T, Tanaka T, Shionoya Y, Yamamoto E, Maruyama R, Nakatsugawa M, Kanaseki T, Tsukahara T, Tamura Y, Sasaki Y, Tokino T, Suzuki H, Kondo T, Takahashi H, Sato N.

Oncotarget. 2016 Aug 2;7(31):50043-50056. doi: 10.18632/oncotarget.10571.

31.

The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.

Matsunaga Y, Adachi Y, Sasaki Y, Koide H, Motoya M, Nosho K, Takagi H, Yamamoto H, Sasaki S, Arimura Y, Tokino T, Carbone DP, Imai K, Shinomura Y.

Mol Carcinog. 2017 Feb;56(2):515-526. doi: 10.1002/mc.22513. Epub 2016 Jun 23.

PMID:
27312358
32.

A genomic screen for long noncoding RNA genes epigenetically silenced by aberrant DNA methylation in colorectal cancer.

Kumegawa K, Maruyama R, Yamamoto E, Ashida M, Kitajima H, Tsuyada A, Niinuma T, Kai M, Yamano HO, Sugai T, Tokino T, Shinomura Y, Imai K, Suzuki H.

Sci Rep. 2016 May 24;6:26699. doi: 10.1038/srep26699.

33.

Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.

Sasaki Y, Tamura M, Koyama R, Nakagaki T, Adachi Y, Tokino T.

World J Gastroenterol. 2016 Feb 21;22(7):2284-93. doi: 10.3748/wjg.v22.i7.2284. Review.

34.

Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing.

Ikeda H, Ishiguro K, Igarashi T, Aoki Y, Hayashi T, Ishida T, Sasaki Y, Tokino T, Shinomura Y.

Onco Targets Ther. 2015 Oct 5;8:2805-15. doi: 10.2147/OTT.S86515. eCollection 2015.

35.

Epigenetic silencing of NTSR1 is associated with lateral and noninvasive growth of colorectal tumors.

Kamimae S, Yamamoto E, Kai M, Niinuma T, Yamano HO, Nojima M, Yoshikawa K, Kimura T, Takagi R, Harada E, Harada T, Maruyama R, Sasaki Y, Tokino T, Shinomura Y, Sugai T, Imai K, Suzuki H.

Oncotarget. 2015 Oct 6;6(30):29975-90. doi: 10.18632/oncotarget.5034.

36.

A Screen for Epigenetically Silenced microRNA Genes in Gastrointestinal Stromal Tumors.

Isosaka M, Niinuma T, Nojima M, Kai M, Yamamoto E, Maruyama R, Nobuoka T, Nishida T, Kanda T, Taguchi T, Hasegawa T, Tokino T, Hirata K, Suzuki H, Shinomura Y.

PLoS One. 2015 Jul 27;10(7):e0133754. doi: 10.1371/journal.pone.0133754. eCollection 2015.

37.

One-Dimensional Sliding of p53 Along DNA Is Accelerated in the Presence of Ca(2+) or Mg(2+) at Millimolar Concentrations.

Murata A, Ito Y, Kashima R, Kanbayashi S, Nanatani K, Igarashi C, Okumura M, Inaba K, Tokino T, Takahashi S, Kamagata K.

J Mol Biol. 2015 Aug 14;427(16):2663-78. doi: 10.1016/j.jmb.2015.06.016. Epub 2015 Jul 2.

PMID:
26143716
38.

Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy.

Mitsuhashi K, Yamamoto I, Kurihara H, Kanno S, Ito M, Igarashi H, Ishigami K, Sukawa Y, Tachibana M, Takahashi H, Tokino T, Maruyama R, Suzuki H, Imai K, Shinomura Y, Yamamoto H, Nosho K.

Oncotarget. 2015 Sep 8;6(26):22114-25.

39.

CRKL oncogene is downregulated by p53 through miR-200s.

Tamura M, Sasaki Y, Kobashi K, Takeda K, Nakagaki T, Idogawa M, Tokino T.

Cancer Sci. 2015 Aug;106(8):1033-40. doi: 10.1111/cas.12713. Epub 2015 Jul 14.

40.

Relation between Ku80 and microRNA-99a expression and late rectal bleeding after radiotherapy for prostate cancer.

Someya M, Yamamoto H, Nojima M, Hori M, Tateoka K, Nakata K, Takagi M, Saito M, Hirokawa N, Tokino T, Sakata K.

Radiother Oncol. 2015 May;115(2):235-9. doi: 10.1016/j.radonc.2015.04.008. Epub 2015 Apr 30.

PMID:
25937401
41.

Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells.

Idogawa M, Ohashi T, Sugisaka J, Sasaki Y, Suzuki H, Tokino T.

Oncotarget. 2014 Sep 15;5(17):7540-8.

42.

MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions.

Ito M, Mitsuhashi K, Igarashi H, Nosho K, Naito T, Yoshii S, Takahashi H, Fujita M, Sukawa Y, Yamamoto E, Takahashi T, Adachi Y, Nojima M, Sasaki Y, Tokino T, Baba Y, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y.

Int J Cancer. 2014 Dec 1;135(11):2507-15. doi: 10.1002/ijc.28920. Epub 2014 Apr 30.

43.

Identification and analysis of large intergenic non-coding RNAs regulated by p53 family members through a genome-wide analysis of p53-binding sites.

Idogawa M, Ohashi T, Sasaki Y, Maruyama R, Kashima L, Suzuki H, Tokino T.

Hum Mol Genet. 2014 Jun 1;23(11):2847-57. doi: 10.1093/hmg/ddt673. Epub 2014 Jan 8.

PMID:
24403050
44.

Forkhead transcription factor FOXF1 is a novel target gene of the p53 family and regulates cancer cell migration and invasiveness.

Tamura M, Sasaki Y, Koyama R, Takeda K, Idogawa M, Tokino T.

Oncogene. 2014 Oct 2;33(40):4837-46. doi: 10.1038/onc.2013.427. Epub 2013 Nov 4.

PMID:
24186199
45.

AKR1B10, a transcriptional target of p53, is downregulated in colorectal cancers associated with poor prognosis.

Ohashi T, Idogawa M, Sasaki Y, Suzuki H, Tokino T.

Mol Cancer Res. 2013 Dec;11(12):1554-63. doi: 10.1158/1541-7786.MCR-13-0330-T. Epub 2013 Oct 18.

46.

Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma.

Aoki Y, Nojima M, Suzuki H, Yasui H, Maruyama R, Yamamoto E, Ashida M, Itagaki M, Asaoku H, Ikeda H, Hayashi T, Imai K, Mori M, Tokino T, Ishida T, Toyota M, Shinomura Y.

Genome Med. 2012 Dec 22;4(12):101. doi: 10.1186/gm402. eCollection 2012. Erratum in: Genome Med. 2013;5(10):88.

47.

Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer.

Shimizu T, Suzuki H, Nojima M, Kitamura H, Yamamoto E, Maruyama R, Ashida M, Hatahira T, Kai M, Masumori N, Tokino T, Imai K, Tsukamoto T, Toyota M.

Eur Urol. 2013 Jun;63(6):1091-100. doi: 10.1016/j.eururo.2012.11.030. Epub 2012 Nov 23.

PMID:
23200812
48.

DNA methyltransferase 1 is essential for initiation of the colon cancers.

Morita R, Hirohashi Y, Suzuki H, Takahashi A, Tamura Y, Kanaseki T, Asanuma H, Inoda S, Kondo T, Hashino S, Hasegawa T, Tokino T, Toyota M, Asaka M, Torigoe T, Sato N.

Exp Mol Pathol. 2013 Apr;94(2):322-9. doi: 10.1016/j.yexmp.2012.10.004. Epub 2012 Oct 9.

PMID:
23064049
49.

Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.

Yamamoto E, Suzuki H, Yamano HO, Maruyama R, Nojima M, Kamimae S, Sawada T, Ashida M, Yoshikawa K, Kimura T, Takagi R, Harada T, Suzuki R, Sato A, Kai M, Sasaki Y, Tokino T, Sugai T, Imai K, Shinomura Y, Toyota M.

Am J Pathol. 2012 Nov;181(5):1847-61. doi: 10.1016/j.ajpath.2012.08.007. Epub 2012 Sep 17.

PMID:
22995252
50.

CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion.

Sasaki Y, Koyama R, Maruyama R, Hirano T, Tamura M, Sugisaka J, Suzuki H, Idogawa M, Shinomura Y, Tokino T.

Cancer Biol Ther. 2012 Dec;13(14):1512-21. doi: 10.4161/cbt.22280. Epub 2012 Sep 18.

Supplemental Content

Loading ...
Support Center